Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$5.64B+144.72%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian James McNamara
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 24,535
- Beta
- 0.24
- Country
- GB
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 3.26
Financials
Revenue
$5.64B+144.7%Net Income
$767.62M+229.5%EBITDA
$1.52B+218.8%Free Cash Flow
$791.80M-41.9%EPS (diluted)
$0.17+237.3%Shares Outstanding (diluted)
4.46B-3.4%Operating Expenses
$2.38BCash & Debt
$821.01MReturn of Capital
$899.59MRevenue by Segment (annual)
$2.86BDividend per Share
$0.06Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.03B | $1.63B | $0.36 |
| 2024 | $11.23B | $1.44B | $0.32 |
| 2023 | $11.30B | $1.05B | $0.24 |
| 2022 | $10.86B | $1.06B | $0.24 |
| 2021 | $9.54B | $1.39B | $0.30 |
| 2020 | $9.89B | $1.15B | $0.24 |
| 2019 | $8.48B | $655.00M | $0.14 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from HLN's reported EPS growth of 17.0% a year over 6 years.
- EPS in 5 years
- $0.80
- Implied price
- $16.75
- Return from $8.82
- 13.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.33 — -5.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 15 | 18 | 21 | 24 | 27 |
|---|---|---|---|---|---|
| 7.0% | -2.8% | 0.8% | 4.0% | 6.8% | 9.3% |
| 12.0% | 1.8% | 5.5% | 8.8% | 11.8% | 14.4% |
| 17.0% | 6.3% | 10.2% | 13.7% | 16.8% | 19.6% |
| 22.0% | 10.8% | 15.0% | 18.6% | 21.8% | 24.7% |
| 27.0% | 15.4% | 19.7% | 23.4% | 26.7% | 29.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (4)
- Newsreuters.com·33d ago·Neutral
Haleon secures better shelf space at Walmart, Target in bid to boost market share Sensodyne toothpaste maker Haleon has quietly negotiated better spots on shelves at U.S. retailers including Walmart and Target , to gain more visibility at a at a time when mounting grocery bills are hitting shopper spending.
View source ↗ - Newsproactiveinvestors.co.uk·42d ago·Positive
Jefferies raises Haleon price target to 410p on margin strength Jefferies has raised its price target for Haleon (Haleon PLC (LSE:HLN, NYSE:HLN), the consumer health company behind Sensodyne and Advil, to 410p from 400p, maintaining its Buy rating. The broker highlighted a 70 basis point margin beat in the first half of the year, though it warned this revived concerns about whether Haleon was investing enough behind growth.
View source ↗ - Newsprnewswire.com·48d ago·Positive
…s, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes LONDON, Aug. 19, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the pricing terms, expiration and results of the offer to buy back any and all of the outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 (the "Notes") of Haleon US Capital LLC's (the "Offeror"), the Company's wholly owned subsidiary (the "Tender Offer"). The Tender Offer has been made upon …
View source ↗ - Newsprnewswire.com·56d ago·Positive
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes LONDON, Aug. 11, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy back any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. Bondholders will receive a price equal to the Total Consideration based on the Reference Yield and the Fixed Spread plus Accrue
View source ↗
Earnings
Thu, Mar 4(in 5 months)
Consensus estimate $0.29 per share
Typical surprise +3.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.28 vs $0.27beat
- Wed, Feb 25$0.26 vs $0.25beat
- Thu, Jul 31$0.24 vs $0.24miss
- Thu, Feb 27$0.23 vs $0.22beat
- Thu, Oct 31$0.23 vs $0.11beat
- Wed, May 1$0.12 vs $0.11beat
Estimates and results for HLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (34d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 14, 2025 (35d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 8, 2024 (19d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (33d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (32d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (31d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 20, 2023 (20d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (42d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.